Bevacizumab for the treatment of glioblastoma

    Authors

    S. Chowdhary;M. Chamberlain

    Comments

    Authors: contact us about adding a copy of your work at [email protected]

    Abbreviated Journal Title

    Expert Rev. Neurother.

    Keywords

    anti-angiogenesis; bevacizumab; glioblastoma; high-grade glioma; MGMT; VEGF; ENDOTHELIAL GROWTH-FACTOR; NEWLY-DIAGNOSED GLIOBLASTOMA; RECURRENT; MALIGNANT GLIOMA; HIGH-GRADE GLIOMAS; METASTATIC COLORECTAL-CANCER; PHASE-II TRIAL; PROMOTER METHYLATION STATUS; SINGLE-AGENT BEVACIZUMAB; BRAIN-TUMOR CONSORTIUM; PLUS IRINOTECAN; Clinical Neurology; Pharmacology & Pharmacy

    Abstract

    Glioblastoma (GB) is the most common adult malignant primary brain tumor that arises from glial precursor cells. Survival in GB is variable ranging from 6 to 20 months notwithstanding current standard of care (SOC) treatment. Therapy has improved, but nonetheless GB is still invariably recurrent and incurable. Treatment options at recurrence include re-operation with or without carmustine (BCNU) wafer implantation (Gliadel), re-irradiation and standard/experimental chemo- or targeted therapy. Recurrent GB radiographic response rates to cytotoxic chemotherapy are less than 10% and median 6-month progression-free survival (PFS6) is 15%. With the recognition of the importance of tumor angiogenesis and the development of targeted therapy based on angiogenic inhibition, two pivotal trials of the VEGF-directed monoclonal antibody, bevacizumab (BEV, Avastin), were conducted in recurrent GB. Based upon the results of these two prospective US trials (median radiographic response rate: 25%; PFS6: 40%), BEV as a single agent was granted accelerated approval in the USA for recurrent GB. This review is a summary of current literature and clinical trials research in the role of BEV for the treatment of newly diagnosed and recurrent GB and potential future use of anti-angiogenic therapies in the management of GB.

    Journal Title

    Expert Review of Neurotherapeutics

    Volume

    13

    Issue/Number

    8

    Publication Date

    1-1-2013

    Document Type

    Review

    Language

    English

    First Page

    937

    Last Page

    949

    WOS Identifier

    WOS:000323539300010

    ISSN

    1473-7175

    Share

    COinS
     

    Accessibility Statement

    This item was created or digitized prior to April 24, 2027, or is a reproduction of legacy media created before that date. It is preserved in its original, unmodified state specifically for research, reference, or historical recordkeeping. In accordance with the ADA Title II Final Rule, the University Libraries provides accessible versions of archival materials upon request. To request an accommodation for this item, please submit an accessibility request form.